Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

BRIGATINIB for Neoplasm malignant: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 39 adverse event reports in the FDA FAERS database where BRIGATINIB was used for Neoplasm malignant.

Most Reported Side Effects for BRIGATINIB

Side Effect Reports % Deaths Hosp.
Death 405 12.3% 404 70
Non-small cell lung cancer 370 11.3% 69 63
Off label use 256 7.8% 64 73
Diarrhoea 239 7.3% 29 91
Metastases to central nervous system 219 6.7% 33 40
Nausea 218 6.6% 24 89
Lung neoplasm malignant 216 6.6% 38 36
Fatigue 201 6.1% 26 61
Blood creatine phosphokinase increased 198 6.0% 10 42
Product dose omission issue 193 5.9% 18 70
Neoplasm progression 172 5.2% 32 24
Drug ineffective 171 5.2% 33 31
Vomiting 122 3.7% 23 47
Dyspnoea 121 3.7% 21 52
Cough 112 3.4% 19 37

Other Indications for BRIGATINIB

Non-small cell lung cancer (1,130) Lung neoplasm malignant (946) Product used for unknown indication (513) Lung adenocarcinoma (148) Non-small cell lung cancer metastatic (82) Neurofibromatosis (70) Lung adenocarcinoma stage iv (60) Bronchial carcinoma (30) Lung cancer metastatic (30) Non-small cell lung cancer stage iv (29)

Other Drugs Used for Neoplasm malignant

PALBOCICLIB (1,996) CAPECITABINE (1,493) PEMBROLIZUMAB (1,135) PACLITAXEL (984) CARBOPLATIN (977) NIVOLUMAB (947) OXALIPLATIN (823) PAZOPANIB (716) CYCLOPHOSPHAMIDE (685) FLUOROURACIL (676)

Related Pages

BRIGATINIB Full Profile All Neoplasm malignant Drugs BRIGATINIB Demographics BRIGATINIB Timeline